Thrivent Financial For Lutherans Nektar Therapeutics Transaction History

Thrivent Financial For Lutherans

$52.6 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 17, 2023	SELL	$0.64 - $3.15 $4,177 - $20,563	-6,528 Reduced 3.39%	186,265 $131,000
Q4 2022 Feb 08, 2023	SELL	$2.03 - $4.28 $1,887 - $3,980	-930 Reduced 0.48%	192,793 $436,000
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $32,579 - $55,085	10,717 Added 5.86%	193,723 $620,000
Q2 2022 Aug 16, 2022	BUY	$3.17 - $6.17 $103,858 - $202,147	32,763 Added 21.81%	183,006 $695,000
Q1 2022 May 13, 2022	BUY	$4.16 - $13.72 $199 - $658	48 Added 0.03%	150,243 $810,000
Q4 2021 Feb 16, 2022	BUY	$10.83 - $18.41 $1.11 Million - $1.88 Million	102,152 Added 212.63%	150,195 $2.03 Million
Q3 2021 Nov 15, 2021	SELL	$13.07 - $18.84 $152,082 - $219,222	-11,636 Reduced 19.5%	48,043 $863,000
Q2 2021 Aug 19, 2021	BUY	$16.52 - $20.4 $185,783 - $229,418	11,246 Added 23.22%	59,679 $1.02 Million
Q1 2021 May 17, 2021	BUY	$16.56 - $25.46 $24,243 - $37,273	1,464 Added 3.12%	48,433 $969,000
Q4 2020 Feb 16, 2021	SELL	$15.77 - $19.03 $233,869 - $282,214	-14,830 Reduced 24.0%	46,969 $798,000
Q3 2020 Nov 10, 2020	SELL	$16.59 - $24.79 $1.16 Million - $1.74 Million	-69,991 Reduced 53.11%	61,799 $1.03 Million
Q2 2020 Aug 12, 2020	BUY	$16.86 - $23.44 $53,968 - $75,031	3,201 Added 2.49%	131,790 $3.05 Million
Q1 2020 May 15, 2020	BUY	$14.47 - $27.96 $1.2 Million - $2.31 Million	82,622 Added 179.74%	128,589 $2.3 Million
Q4 2019 Feb 13, 2020	BUY	$15.87 - $23.12 $729,496 - $1.06 Million	45,967 New	45,967 $992,000
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $132,642 - $284,501	-7,844 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$31.0 - $36.3 $2,449 - $2,867	79 Added 1.02%	7,844 $279,000
Q1 2019 May 14, 2019	BUY	$31.58 - $46.35 $22,832 - $33,511	723 Added 10.27%	7,765 $261,000
Q4 2018 Feb 15, 2019	BUY	$30.43 - $56.65 $3,773 - $7,024	124 Added 1.79%	7,042 $231,000
Q3 2018 Nov 15, 2018	BUY	$46.46 - $68.49 $7,108 - $10,478	153 Added 2.26%	6,918 $422,000
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $1,896 - $4,282	41 Added 0.61%	6,765 $330,000
Q1 2018 May 08, 2018	SELL	$57.4 - $108.44 $5.22 Million - $9.86 Million	-90,931 Reduced 93.11%	6,724 $714,000
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $44,313 - $116,462	1,925 Added 2.01%	97,655 $5.83 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $1.7 Million - $2.3 Million	95,730	95,730 $2.3 Million

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$14.8 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$14.1 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$12.2 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$8.74 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$8.56 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.

Account